335 related articles for article (PubMed ID: 2107058)
21. A longitudinal study of changes in endometrial microvascular density in Norplant implant users.
Hickey M; Simbar M; Young L; Markham R; Russell P; Fraser IS
Contraception; 1999 Feb; 59(2):123-9. PubMed ID: 10361627
[TBL] [Abstract][Full Text] [Related]
22. Subdermal contraceptive implants.
Peralta O; Diaz S; Croxatto H
J Steroid Biochem Mol Biol; 1995 Jun; 53(1-6):223-6. PubMed ID: 7626459
[TBL] [Abstract][Full Text] [Related]
23. Hormonal implants: contraception for a new century.
Darney PD
Am J Obstet Gynecol; 1994 May; 170(5 Pt 2):1536-43. PubMed ID: 8178903
[TBL] [Abstract][Full Text] [Related]
24. Contraception with progestogens and progesterone during lactation.
Shaaban MM
J Steroid Biochem Mol Biol; 1991; 40(4-6):705-10. PubMed ID: 1835650
[TBL] [Abstract][Full Text] [Related]
25. Plasma levonorgestrel levels and ovarian function during the use of a levonorgestrel-releasing intracervical contraceptive device.
Ratsula K; Toivonen J; Lähteenmäki P; Luukkainen T
Contraception; 1989 Feb; 39(2):195-204. PubMed ID: 2495893
[TBL] [Abstract][Full Text] [Related]
26. Effect of preovulatory insertion of Norplant implants over luteinizing hormone secretion and follicular development.
Brache V; Alvarez F; Faundes A; Cochon L; Thevenin F
Fertil Steril; 1996 Jun; 65(6):1110-4. PubMed ID: 8641481
[TBL] [Abstract][Full Text] [Related]
27. Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel.
Brenner PF; Mishell DR; Stanczyk FZ; Goebelsmann U
Am J Obstet Gynecol; 1977 Sep; 129(2):133-40. PubMed ID: 900174
[TBL] [Abstract][Full Text] [Related]
28. Correlation between the serum norethindrone (NET) levels attained after insertion of a silastic implant releasing norethindrone acetate and the endogenous hormones particularly progesterone.
Laumas V; Jain AK; Jha P; Rahman SA; Kumar D; Malik BK; Sarkar NN; Takkar D; Hingorani V; Laumas KR
Contraception; 1981 Feb; 23(2):211-25. PubMed ID: 6786828
[TBL] [Abstract][Full Text] [Related]
29. Serum levels of FSH, LH, estradiol-17 beta and progesterone following the administration of a combined oral contraceptive containing 20 micrograms ethinylestradiol.
Carlström K; Lunell NO; Zador G
Gynecol Obstet Invest; 1978; 9(6):304-11. PubMed ID: 754992
[TBL] [Abstract][Full Text] [Related]
30. Suppression of ovarian function with the transdermally given synthetic progestin ST 1435.
Laurikka-Routti M; Haukkamaa M; Lähteenmäki P
Fertil Steril; 1992 Oct; 58(4):680-4. PubMed ID: 1426309
[TBL] [Abstract][Full Text] [Related]
31. Expression of progesterone receptor mRNA in the endometrium during the normal menstrual cycle and in Norplant users.
Lau TM; Witjaksono J; Affandi B; Rogers PA
Hum Reprod; 1996 Dec; 11(12):2629-34. PubMed ID: 9021364
[TBL] [Abstract][Full Text] [Related]
32. Mode of action of dl-norgestrel and ethinylestradiol combination in postcoital contraception. III. Effect of preovulatory administration following the luteinizing hormone surge on ovarian steroidogenesis.
Ling WY; Wrixon W; Acorn T; Wilson E; Collins J
Fertil Steril; 1983 Nov; 40(5):631-6. PubMed ID: 6628707
[TBL] [Abstract][Full Text] [Related]
33. Ovarian function during use of a levonorgestrel-releasing IUD.
Barbosa I; Bakos O; Olsson SE; Odlind V; Johansson ED
Contraception; 1990 Jul; 42(1):51-66. PubMed ID: 2117516
[TBL] [Abstract][Full Text] [Related]
34. Plasma levonorgestrel and progesterone levels in women treated with silastic covered rods containing levonorgestrel.
Croxatto HB; Díaz S; Brandeis A; Pavez M; Johansson ED
Contraception; 1985 Jun; 31(6):643-54. PubMed ID: 3930143
[TBL] [Abstract][Full Text] [Related]
35. Phase I comparative clinical trial with subdermal implants--bioabsorbable levonorgestrel or norethisterone pellet fused with cholesterol.
Joshi UM; Joshi JV; Donde UM; Sankoli GM; Virkar KD; Saxena BN
Contraception; 1985 Jan; 31(1):71-82. PubMed ID: 3921309
[TBL] [Abstract][Full Text] [Related]
36. The effect of levonorgestrel administered in large doses at different stages of the cycle on ovarian function and endometrial morphology.
Landgren BM; Johannisson E; Aedo AR; Kumar A; Shi YE
Contraception; 1989 Mar; 39(3):275-89. PubMed ID: 2496951
[TBL] [Abstract][Full Text] [Related]
37. Timing of onset of contraceptive effectiveness in Norplant implant users. II. Effect on the ovarian function in the first cycle of use.
Brache V; Blumenthal PD; Alvarez F; Dunson TR; Cochon L; Faundes A
Contraception; 1999 Apr; 59(4):245-51. PubMed ID: 10457869
[TBL] [Abstract][Full Text] [Related]
38. Plasma levels of levonorgestrel and free levonorgestrel index in women using NORPLANT implants or two covered rods (NORPLANT-2).
Olsson SE; Odlind V; Johansson ED; Nordström ML
Contraception; 1987 Mar; 35(3):215-28. PubMed ID: 3111784
[TBL] [Abstract][Full Text] [Related]
39. Cytokeratins 8, 18 and 19 in endometrial epithelial cells during the normal menstrual cycle and in women receiving Norplant.
Wonodirekso S; Au CL; Hadisaputra W; Affandi B; Rogers PA
Contraception; 1993 Nov; 48(5):481-93. PubMed ID: 7506133
[TBL] [Abstract][Full Text] [Related]
40. Contraception with subdermal implants releasing levonorgestrel. A clinical and pharmacological study.
Olsson SE
Acta Obstet Gynecol Scand Suppl; 1987; 142():1-45. PubMed ID: 3116821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
